Literature DB >> 19879228

Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis).

Tonie E Rocke1, Keith P Iams, Sandra Dawe, Susan R Smith, Judy L Williamson, Dennis M Heisey, Jorge E Osorio.   

Abstract

In previous studies, we demonstrated protection against plague in mice and prairie dogs using a raccoon pox (RCN) virus-vectored vaccine that expressed the F1 capsular antigen of Yersinia pestis. In order to improve vaccine efficacy, we have now constructed additional RCN-plague vaccines containing two different forms of the lcrV (V) gene, including full-length (Vfull) and a truncated form (V307). Mouse challenge studies with Y. pestis strain CO92 showed that vaccination with a combination of RCN-F1 and the truncated V construct (RCN-V307) provided the greatest improvement (P=0.01) in protection against plague over vaccination with RCN-F1 alone. This effect was mediated primarily by anti-F1 and anti-V antibodies and both contributed independently to increased survival of vaccinated mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879228     DOI: 10.1016/j.vaccine.2009.10.043

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.

Authors:  Debaditya Bhattacharya; Joan Mecsas; Linden T Hu
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

2.  Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.

Authors:  Joseph N Brewoo; Tim D Powell; Dan T Stinchcomb; Jorge E Osorio
Journal:  Vaccine       Date:  2010-07-12       Impact factor: 3.641

3.  Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

Authors:  Laura Evgin; Markus Vähä-Koskela; Julia Rintoul; Theresa Falls; Fabrice Le Boeuf; John W Barrett; John C Bell; Marianne M Stanford
Journal:  Mol Ther       Date:  2010-02-16       Impact factor: 11.454

Review 4.  Plague vaccines: current developments and future perspectives.

Authors:  Valentina A Feodorova; Vladimir L Motin
Journal:  Emerg Microbes Infect       Date:  2012-11-07       Impact factor: 7.163

Review 5.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

6.  Virally-vectored vaccine candidates against white-nose syndrome induce anti-fungal immune response in little brown bats (Myotis lucifugus).

Authors:  Tonie E Rocke; Brock Kingstad-Bakke; Marcel Wüthrich; Ben Stading; Rachel C Abbott; Marcos Isidoro-Ayza; Hannah E Dobson; Lucas Dos Santos Dias; Kevin Galles; Julia S Lankton; Elizabeth A Falendysz; Jeffrey M Lorch; J Scott Fites; Jaime Lopera-Madrid; J Paul White; Bruce Klein; Jorge E Osorio
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.996

7.  Sylvatic plague vaccine: a new tool for conservation of threatened and endangered species?

Authors:  Rachel C Abbott; Jorge E Osorio; Christine M Bunck; Tonie E Rocke
Journal:  Ecohealth       Date:  2012-07-31       Impact factor: 4.464

8.  Impact of Sylvatic Plague Vaccine on Non-target Small Rodents in Grassland Ecosystems.

Authors:  Gebbiena M Bron; Katherine L D Richgels; Michael D Samuel; Julia E Poje; Faye Lorenzsonn; Jonathan P Matteson; Jesse T Boulerice; Jorge E Osorio; Tonie E Rocke
Journal:  Ecohealth       Date:  2018-05-09       Impact factor: 4.464

9.  A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague.

Authors:  Tonie E Rocke; Brock Kingstad-Bakke; Willy Berlier; Jorge E Osorio
Journal:  Vaccines (Basel)       Date:  2014-10-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.